Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics co...
CareDx, Inc., headquartered in Brisbane, Califo...
Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...
Jounce Therapeutics is a clinical stage immunot...
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is...
Merrimack is a biopharmaceutical company based ...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical c...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a...
We are a clinical-stage immuno-oncology company specializing in the development an...
We are a clinical-stage immuno-oncology company...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
Join the National Investor Network and get the latest information with your interests in mind.